Drugs / ATA3219
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06429800 | Apr 2025 | lupus nephritis, systemic lupus erythematosus | Atara Biotherapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT06256484 | Sep 2024 → Mar 2025 | B-cell non-Hodgkin lymphoma | Atara Biotherapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-01-21 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 atarabio.com ↗
U.S. FDA issues clinical hold on EBVALLO ™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) |
| 2024-05-29 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting atarabio.com ↗
today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. |
| 2024-02-29 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy atarabio.com ↗
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). |
| 2024-02-14 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis atarabio.com ↗ |
| 2023-08-08 | Atara Biotherapeutics | Regulatory Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress atarabio.com ↗ |
| 2021-02-08 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience atarabio.com ↗
Atara will also report additional data sets related to tab-cel ® , as well as preclinical findings demonstrating the potent anti-tumor activity of the Company’s next-generation CD19-based CAR T, ATA3219. |
| 2020-12-07 | Atara Biotherapeutics | Results Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting atarabio.com ↗
Preclinical findings with ATA3219 show potent antitumor activity both in vitro and in vivo, with long-term persistence and no evidence of allocytoxicity in vivo |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATA3219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06429800 ↗ |
| Modality | Cell therapy | “allogeneic anti-CD19 chimeric antigen receptor T-cell” NCT06256484 ↗ |
| Route | Intravenous | “administered intravenously on Day 1” NCT06256484 ↗ |
| Target | CD19 | “anti-CD19” NCT06256484 ↗ |